s22-9122_8k.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 29, 2009
ADEONA
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
(State
or other jurisdiction of incorporation)
|
01-12584
(Commission
File No.)
|
13-3808303
(IRS
Employer Identification No.)
|
3930
Varsity Drive, Ann Arbor, Michigan 48108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (734) 332-7800
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors and Certain Officers; Election of
Directors;Appointment of Certain Officer; Compensatory Arrangements of
CertainOfficers
On March 29, 2009, Mr. Nicholas
Stergis, resigned from his position as Chief Executive Officer of the
Company. Mr Stergis continues to serve as Vice–Chairman of the Board
of Directors of the Company.
On March 29, 2009, Steve H. Kanzer,
C.P.A., J.D., the Company’s Chairman of the Board, was appointed to the
additional positions of Chief Executive Officer and
President. Information regarding Mr. Kanzer’s service with the
Company, other business experience and a description of his employment agreement
is included under Part III, Item 10 of the Company’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2008, and is incorporated herein by
reference.
A copy of the Press Release announcing
Mr. Stergis’ resignation and the appointment of Mr. Kanzer is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01. Financial
Statements and Exhibits
(d) Exhibits. The
following exhibits are being furnished as part of this Report.
|
Exhibit
Number
|
Description of Exhibit
|
|
|
|
|
99.1
|
Press
Release dated April 1, 2009
|
|
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ADEONA
PHARMACEUTICALS, INC. |
| |
|
| Date: April
2, 2009 |
By: /s/
Steve H.
Kanzer
|
| |
Name: Steve
H. Kanzer
|
| |
Its:
President and Chief Executive
Officer
|
EXHIBIT
INDEX
|
Exhibit
Number
|
Description of Exhibit
|
|
|
|
|
99.1
|
Press
Release dated April 1, 2009
|
|
|
|
|
|
|
4